Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma

In the version of the article initially published, the far-right column of the lower panel in Fig. 2c was missing and has now been added, as seen in Fig. 1, below. Additionally, the sentence “L.P. is a founder and shareholder of Apricot Therapeutics - a precision oncology spin-off from the University of Zurich - based on 4i drug response profiling” was missing from the Competing interests statement and has now been added. These corrections have been made to the HTML and PDF versions of the article.

Keywords

Drug therapy, Erratum, Human, Male, Diagnosis

Subject (DDC)

610 - Medizin und Gesundheit

Project

Event

Exhibition start date

Exhibition end date

Conference start date

Conference end date

Date of the last check

ISBN

ISSN

1078-8956
1546-170X

Language

English

Created during FHNW affiliation

Yes

Strategic action fields FHNW

Publication status

Published

Review

Peer review of the complete publication

Open access category

Gold

License

Citation

Miglino, N., Toussaint, N. C., Ring, A., Bonilla, X., Tusup, M., Gosztonyi, B., Mehra, T., Gut, G., Jacob, F., Chevrier, S., Lehmann, K.-V., Casanova, R., Jacobs, A., Sivapatham, S., Boos, L., Rahimzadeh, P., Schuerch, M., Sobottka, B., Chicherova, N., et al. (2025). Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma. Nature Medicine, 31, 2817–2818. https://doi.org/10.1038/s41591-025-03904-3

Full item page